Recognizing that oncology practices are struggling with the pandemic, the Center for Medicare and Medicaid Innovation has eased some performance requirements.
The Oncology Care Model (OCM) has served as a proving ground for the value of biosimilars, as various studies presented at this year’s American Society of Clinical Oncology meeting show.
The model of value-based care established through CMS’ Center for Medicare and Medicaid Innovation (CMMI) was intended to terminate next year and be replaced. It’s now among a number of models that CMS has decided to extend owing to the disruption caused by the coronavirus disease 2019 (COVID-19) pandemic. The OCM will now extend 1 additional year, until mid-2022.
A key feature of the model was that practices would share the upside financial gain that CMS received from savings achieved by the model. Eventually, they also would have to share the financial downside (ie, negative savings) as they learned how to manage the model's complex requirements.
As part of the COVID-19 arrangements, the 175 practices enrolled in the model will have the option to forgo the upside and downside risks associated with performance reporting periods during the pandemic. Practices have seen reduced flow of patients, and the practice of oncology has been made more complicated by the need to ensure the safety of clinicians and patients. Clinical trial activities also have been disrupted.
As one of the concessions offered by CMS for practices that choose not to forgo the upside or downside risk, episodes of care affected by COVID-19 will not be factored into their performance evaluations.
“When it comes to a pandemic of the proportion we’re now experiencing, as part of ensuring that value-based payments are sustainable, the models must be adjustable to address the uniqueness of the current situation,” CMS Administrator Seema Verma said in a blog post in Health Affairs.
For more about the CMMI decision, read the full story at AJMC.com.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.